A Molecular Framework for Delirium

Area of Science:

• Neuroscience
• Gerontology
• Pharmacology

Background:

• Delirium impacts over 2.6 million older adults annually in the US, increasing mortality and healthcare costs ($164 billion).
• The molecular basis of delirium is poorly understood, hindering pharmacotherapy development.
• Cognitive deficits in delirium, particularly attention and working memory (WM) impairments, localize to the dorsolateral prefrontal cortex (dlPFC).

Purpose of the Study:

• To review the neural circuitry and molecular mechanisms of WM and dlPFC function.
• To explore the dlPFC as a potential common endpoint for cognitive changes in delirium, especially in Alzheimer's disease (AD) patients.
• To identify potential molecular targets for delirium treatment by understanding dlPFC function.

Main Methods:

• Review of preclinical studies on dlPFC function and pharmacology.
• Analysis of the role of monoaminergic and anticholinergic systems in dlPFC-mediated cognition.
• Examination of the therapeutic potential of medications like guanfacine (α-2 agonists) in delirium.

Main Results:

• Preclinical dlPFC models replicate delirium-related pharmacological observations (e.g., anticholinergic sensitivity, inverted-U monoaminergic response).
• The dlPFC exhibits sensitivity to neurotransmitter levels, with optimal WM performance within a narrow signaling range.
• α-2 agonists like guanfacine show promise for delirium treatment by modulating dlPFC activity.

Conclusions:

• The dlPFC is a critical brain region implicated in the cognitive deficits of delirium.
• Understanding dlPFC molecular mechanisms and circuitry may reveal new therapeutic targets for delirium.
• Further research into α-2 agonists and dlPFC function could lead to novel pharmacotherapies for this prevalent condition.